Negative
●
Proactive Investors
●
2 months ago
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the company's valuation, after its Wainua drug failed a closely watched Phase III trial in a form of heart disease. The drop propelled the stock to the top of the FTSE 100 losers' list.